Cost-effectiveness of 5-hydroxytryptamine3 receptor antagonists: A retrospective comparison of ondansetron and granisetron [1]

Anti-Cancer Drugs

Volumn 7, Issue 1, 1996, Pages 127-130

  Thwaites, R ^a   Parasuraman, T V ^a   Paska, W ^a   Johnson, N ^a   Bosanquet, N ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GRANISETRON; ONDANSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST;

CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VOMITING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; NOTE; SALVAGE THERAPY;

COST-BENEFIT ANALYSIS; GRANISETRON; NAUSEA; ONDANSETRON; SALVAGE THERAPY; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0029665266     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (0)